| First Author | Wang X | Year | 2014 |
| Journal | J Neurosci | Volume | 34 |
| Issue | 18 | Pages | 6182-9 |
| PubMed ID | 24790189 | Mgi Jnum | J:223181 |
| Mgi Id | MGI:5648169 | Doi | 10.1523/JNEUROSCI.5093-13.2014 |
| Citation | Wang X, et al. (2014) Optogenetic stimulation of locus ceruleus neurons augments inhibitory transmission to parasympathetic cardiac vagal neurons via activation of brainstem alpha1 and beta1 receptors. J Neurosci 34(18):6182-9 |
| abstractText | Locus ceruleus (LC) noradrenergic neurons are critical in generating alertness. In addition to inducing cortical arousal, the LC also orchestrates changes in accompanying autonomic system function that compliments increased attention, such as during stress, excitation, and/or exposure to averse or novel stimuli. Although the association between arousal and increased heart rate is well accepted, the neurobiological link between the LC and parasympathetic neurons that control heart rate has not been identified. In this study, we test directly whether activation of noradrenergic neurons in the LC influences brainstem parasympathetic cardiac vagal neurons (CVNs). CVNs were identified in transgenic mice that express channel-rhodopsin-2 (ChR2) in LC tyrosine hydroxylase neurons. Photoactivation evoked a rapid depolarization, increased firing, and excitatory inward currents in ChR2-expressing neurons in the LC. Photostimulation of LC neurons did not alter excitatory currents, but increased inhibitory neurotransmission to CVNs. Optogenetic activation of LC neurons increased the frequency of isolated glycinergic IPSCs by 27 +/- 8% (p = 0.003, n = 26) and augmented GABAergic IPSCs in CVNs by 21 +/- 5% (p = 0.001, n = 26). Inhibiting alpha1, but not alpha2, receptors blocked the evoked responses. Inhibiting beta1 receptors prevented the increase in glycinergic, but not GABAergic, IPSCs in CVNs. This study demonstrates LC noradrenergic neurons inhibit the brainstem CVNs that generate parasympathetic activity to the heart. This inhibition of CVNs would increase heart rate and risks associated with tachycardia. The receptors activated within this pathway, alpha1 and/or beta1 receptors, are targets for clinically prescribed antagonists that promote slower, cardioprotective heart rates during heightened vigilant states. |
